Laquinimod
· first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of
relapsing-remitting multiple sclerosis
· data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced
early treatment with laquinimod compared with delayed treatment
Tasquinimod
· the Phase III study is proceeding according to plan
ANYARA
· Phase II/III study in renal cell cancer concluded
· Results presented:
- study did not achieve primary clinical endpoint
- doubling of progression-free survival and overall survival in 25 percent of patients
- planning of the continued clinical development ongoing
57-57 (paquinimod)
· clinical trial in systemic sclerosis concluded, evaluation underway
ISI
· focus on submission of patents
Other information
· Active Biotech raised SEK 270 M through a directed share issue to Investor
| Jan - Mar | Jan - Dec | |||
| (SEK M) | 2013 | 2012 | 2012 | |
| 2.4 | 2.6 | 227.9 | |
| -77.0 | -100.7 | -163.2 | |
| -78.0 | -99.0 | -175.0 | |
| -1.10 | -1.44 | -2.54 | |
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund
Tel: 046 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com (http://www.activebiotech.com/)
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Thomson Reuters ONE
